Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Mama >98.0% (GC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates ma maualuga mama
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igoa Vailaau | Methyl 4-Amino-2-Methoxybenzoate |
Synonyms | 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester |
Numera CAS | 27492-84-8 |
CAT Numera | RF-PI1974 |
Tulaga Fa'asoa | I Fa'atauga, Oloa Fua e O'o i Tone |
Fuafua mole | C9H11NO3 |
Molecular Weight | 181.19 |
Malosi | 1.179±0.060g/cm3 |
Fa'ailoga | Ruifu Chemical |
Aitema | Fa'amatalaga |
Fa'aaliga | Pa'epa'e i le Pa'epa'e Pa'epa'e po'o tioata |
Mama / Suʻesuʻega Metotia | >98.0% (GC) |
Mama / Suʻesuʻega Metotia | 97.5~102.5 (Titration e le o ninaqueous) |
Lisi Lisi | 157.0~161.0 ℃ |
Ma'imau ile Fa'amago | <1.00% |
Aofa'i Fa'aleaga | <2.0% |
Alaleo Infrared | E tusa ai ma le Fauga |
Proton NMR Alaleo | E tusa ai ma le Fauga |
Tulaga Su'ega | Pisinisi Tulaga |
Fa'aoga | Intermediate o Lenvatinib Mesylate (CAS: 857890-39-2) |
afifi: Fagu, ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau
Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu
Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) e mafai ona faʻaaogaina e fai ma sui o le Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib o se vailaʻau o le kanesa o le thyroid na atiaʻe e le Eisai Corporation o Iapani (Code: E7080), o loʻo iai i le inhibitor of oral multi-receptor tyrosine kinase (RTK) ma e mafai ona faʻalavelaveina le gaioiga kinase o le vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), ma VEGFR3 (FLT4).Lenvatinib e mafai foi ona taofia le aʻafia o isi RTK i pathological angiogenesis, tuputupu aʻe o le tuma, ma le alualu i luma o le kanesa sei vagana ai a latou galuega masani feaveaʻi e aofia ai le fibroblast growth factor (FGF) receptors FGFR1, 2, 3, ma le 4;e maua mai le platelets growth factor receptor (PDGFR [alpha]), KIT, ma le RET.[Fa'ailoga]: Lenvatinib e talafeagai mo togafitiga o gasegase o thyroid kanesa o le toe fa'afo'i mai i le lotoifale po'o le metastasis ituaiga, tulaga alualu i luma ma le radioactive iodine-refractory differentiated type.I le aso 13 o Fepuari, 2015, na faʻamaonia ai e le US FDA le vailaʻau faʻamaʻi faʻamaʻi Lenvatinib mo togafitiga o le kanesa thyroid.Lenvatinib o se fa'atosina enzyme e tele-target, e mafai ona fa'alavelaveina le VEGFR2 ma le VEGFR3 (vascular endothelial growth factor receptor).Ole igoa tau fefa'ataua'iga ole Lenvatinib ole Lenvima.I le aso 20 o Me, 2015, na faʻamaonia ai e le European Medicines Agency (EMA) le Lenvatinib mo le togafitia o faʻamaʻi pipisi, faʻa-lotoifale poʻo metastatic differentiated (papillary, follicular, Hurthle type) thyroid cancer (DTC).I le faamasinoga, o le umi o le ola mo tagata mamaʻi o le radioactive iodine-refractory DTC na togafitia ma Lenvatinib e 18 masina ae o le tau mo tagata mamaʻi e ave placebo e naʻo le 3 masina.